EVALUATION OF RESIDUAL QUANTITY OF ADENO-CRE IN THE MOUSE CAGES OF INDIVIDUALLY VENTILATED RACK AFTER INOCULATION OF MICE WITH ADENO-CRE VIRUS.

Jatinder Gulani, DVM, PhD, DACLAM Institutional Attending Veterinarian Frederick National Laboratory for Cancer Research



Biosaf	ety Level Matrix			
	Containment Level Require		1	
Biological Materials for Direct Inoculation into Animals	Practices/Procedures/Manipulations	Necropsy	11	
Adenovirus/Adeno-Cre; Adenoviral Vectors	BSL 2	ABSL 2 for 2 weeks, then ABSL 1 with required cage change prior to transition	BSL 2	
Known Human Pathogens/Microorganisms/Bacteria (Refer to IBC since specific strains of bacteria	BSL 2	ABSL 2 for duration of the	Follow LASP SOP 3.049F for ABSL 2	1
and other infectious materials in Risk Group 1 may not require this containment level). Known Mouse Pathogens (with potential zoonotic effects)	BSL 2	ABSL 2 for duration of the	BSL 2	1
Vaccinia	BSL 2	ABSL 2 for duration of the study	BSL 2	1
Biological Materials of Murine Origin	Containment Level Require	nents	Necropsy	
-	Practices/Procedures/Manipulations	Animal Housing		
Unmodified Murine Cells	BSL1	ABSL1	BSL 1	
Murine Cells Transfected with Non-Viral Elements	BSL 1	ABSL1	BSL 1	
Modified Murine Cells – Transduced with MLV-Based Vector with an Insert that was Designated as Benign (i.e. GFP) by the IBC*	BSL 1	ABSL 1	BSL 1	
Modified Murine Cells – Transduced with MLV-Based Vector with an Insert that was Designated as Non-Benign (e.g. Oncogene) by the IBC*	BSL2	ABSL 2 for the duration of the study	BSL 2	
Modified Murine Cells – Transduced with Lentiviral Vector **	BSL 2	ABSL 2 for 10 days, then	BSL 2	
Modified Murine Cells-Transduced with Adenoviral Vector ***	BSL 2	ABSL 2 for 2 weeks, then ABSL 1***	BSL 2	₽
	Containment Level Require			
Biological Materials of Human Origin	Practices/Procedures/Manipulations	Animal Housing	Necropsy	
Known Human Pathogens/Microorganisms/Bacteria (Refer to IBC since specific strains of bacteria and other infectious materials in Risk Group 1 may not require this containment level).	Biosafety Level to be determined by IBC review	N/A	N/A	
Unmodified Human Cell Lines	BSL 2	ABSL 1	BSL 2	
Modified Human Cells-Transfected with Non-Viral Elements	BSL 2	ABSL 1	BSL 2	
Modified Human Cells-Transduced with MLV-Based Vectors with An Insert that was Designated as Benign (i.e. GFP) by the IBC*	BSL 2	ABSL 1	BSL 2	
Modified Human Cells-Transduced with MLV-Based Vectors with An Insert that was Designated as Non-Benign (i.e. Oncogene) by the IBC*	BSL 2	ABSL 2 for the duration of the study	BSL 2	
Modified Human Cells – Transduced with Lentiviral Vector **	BSL 2	ABSL 2 for 10 days, then ABSL 1**	BSL 2	
	Biological Materials for Direct Inoculation into Animals Adenovirus/Adeno-Cre; Adenoviral Vectors Known Human Pathogens/Microorganismy/Bacteria (Refer to IBC since specific strains of bacteria and other infectious materials in Risk Group 1 may not require this containment level). Known Mouse Pathogens (with potential zoonotic effects) Vaccinia Biological Materials of Murine Origin Unmodified Murine Cells Murine Cells Transduced with MLV-Based Vector with an Insert that was Designated as Non-Benjn (Le , GPP) by the IBC* Modified Murine Cells-Transduced with Adenoviral Vector *** Biological Materials of Human Origin Known Human Pathogens/Microorganisms/Bacteria (Refer to IBC since specific strains of bacteria and other infectious materials in Risk Group 1 may not require this containment level). Modified Murine Cells-Transduced with Methoviral Vector *** Biological Materials of Human Origin Known Human Pathogens/Microorganisms/Bacteria (Refer to IBC since specific strains of bacteria and other infectious materials in Risk Group 1 may not require this containment level). Unmodified Human Cells-Transduced with MLV-Based Vectors with An Insert that was Designated as Being (IC, GP) by the IBC* Modified Human Cells-Transduced with MLV-Based Vectors with An Insert that was Designated as Modified Human Cells-Transduced with MLV-Based Vectors with An Insert that was Designated as Being (IC, GP) by the IBC* Modified Human Cells-Transduced with MLV-Based Vectors with An Insert that was Designated as Being (IC, GP) by the IBC* Modified Human Cells-Transduced with MLV-Based Vectors with An Insert that was Designated as Being (IC, GP) by the IBC* Modified Human Cells-Transduced with MLV-Based Vectors with An Insert that was Designated as Being (IC, GP) by the IBC* Modified Human Cells-Transduced with MLV-Based Vectors with An Insert that was Designated as Being (IC, GP) by the IBC*	Biological Materials for Direct Inoculation into Animals Containment Level Requires Adenovirus/Adeno-Cre; Adenoviral Vectors BSL 2 Known Human Pathogens/MicroorganismyBacterie (Refer to IBC since specific strains of bacteria and other infectious materials in Risk Group 1 may not require this containment Level). BSL 2 Known Human Cells-Transduced with MLV-Based Vector with an Insert that was Designated as Non-Bengin (Leg. Oncogene) by the IBC* BSL 2 Modified Murine Cells-Transduced with MLV-Based Vector with an Insert that was Designated as Non-Bengin (Leg. Oncogene) by the IBC* BSL 2 Modified Murine Cells-Transduced with MLV-Based Vector with an Insert that was Designated as Non-Bengin (Leg. Oncogene) by the IBC* BSL 2 Modified Murine Cells-Transduced with Adenoviral Vector ** BSL 2 Modified Murine Cells-Transduced with Adenoviral Vector *** BSL 2 Modified Murine Cells-Transduced with Adenoviral Vector *** BSL 2 Modified Murine Cells-Transduced with MLV-Based Vector with an Insert that was Designated as Non-Bengin (Leg. Oncogene) by the IBC* Biological Materials of Human Origin Modified Murine Cells-Transduced with Adenoviral Vector *** BSL 2 Modified Murine Cells-Transduced with MLV-Based Vectors with an Insert that was Designated as Non-Bengin (Leg. Oncogene) by the IBC* Biological Materials of Human Origin Modified Murine Cells-Transduced with MLV-Based Vectors	Biological Materials for Direct Inoculation Into Animals Containment Level Requirements Adenoviral/Adeno-Cre; Adenoviral Vectors Abis 1.2 for 3 resets, then Adenoviral/Adeno-Cre; Adenoviral Vectors Abis 2.1 for 3 resets, then Indender Pathogens/McorogrammyRestevel Adeleste JBC cinca specific strains of bactoria BBI 2 Abis 2.1 for 3 resets, then Indender Pathogens/McorogrammyRestevel Adeleste JBC cinca specific strains of bactoria BBI 2 Abis 2.1 for duration of the Indender Pathogens/McorogrammyRestevel Adeleste JBC cinca specific strains of bactoria BBI 2 Abis 2.1 for duration of the Indender Pathogens/McorogrammyRestevel Adeleste JBC cinca specific strains of bactoria BBI 2 Abis 2.1 for duration of the Indender Pathogens/McorogrammyRestevel Adeleste JBC BBI 2 Abis 2.1 for duration of the Indender Battorials of Murine Origin Containment Level Requirements BBI 1 ABIS 1 Murine Cells Transduced with Mur-Mased Vector with an Insert that was Designated BSI 1 ABIS 1 ABIS 1 Modified Murine Cells Transduced with Muread Vector with an Insert that was Designated BSI 2 ABIS 1 ABIS 1 Modified Murine Cells Transduced with Muread Vector with an Insert that was Designated BSI 2 ABIS 1 ABIS 1	Biosafety Level Annual Housing Necropsy Amounal/Adems Cre; Ademoiral Years 85.2 ASS.1 full required are for to transition of the Ass.2 85.2 Amounal/Adems Cre; Ademoiral Years 85.2 ASS.2 for diarism of the Ass.2 85.2 Amounal/Adems Cre; Ademoiral Years 85.2 ASS.2 for diarism of the Ass.2 85.2 Amounal/Adems Cre; Ademoiral Years 85.2 ASS.2 for diarism of the Ass.2 85.2 Amounal/Adems Cre; Ademoiral Years 85.2 ASS.2 for diarism of the Ass.2 85.2 Amounal/Adems Cre; Ademoiral Years 85.2 ASS.2 for diarism of the Ass.2 85.2 Amounal/Adems Cre; Ademoiral Years 85.2 ASS.2 for diarism of the SS.2 85.2 Amounal Years 85.2 ASS.2 for diarism of the SS.2 85.2 Amounal Years 85.1 ASS.2 for diarism of the SS.2 85.2 Amounal Years ASS.1 ASS.1 85.1 85.1 Amounal Years ASS.1 ASS.1 85.1 85.1 85.1 85.1 85.1 85.1 85.1 85.1 85.1 85.1 85.1 85.1 85.1 85.1 85.1 85.1 85.1

CHALLENGES WITH ABSL-2 HOUSING

- Providing routine husbandry care is labor intensive.
- Operations are costly.
- Limited availability of animal housing space, which meets ABSL-2 standards.
- Difficulty in procuring PPE during COVID times.

FIRST EXPERIMENT



8–10-week-old female C57BL/6J mice

- Intratracheal inoculation with 2.5 x 10⁷ PFU Adeno-Cre Virus
- Intratracheal inoculation with Saline
- Sample type: Dry Swab of the mouse body, mouse cage, biosafety cabinet and floor of the animal holding room
- Sampling time points: day 10, 14, 21 and 28 post-inoculation.
- PCR detection of Cre gene (215 bp) which is part of the Adeno-Cre was utilized to assess the presence of Adeno-Cre virus
- PCR detection of mouse genomic DNA (IL2 exon3 – 300 bp) was used as the positive control.

Adeno-Cre: Replicative defective human adenovirus serotype 5 with Cre-recombinase

MULTIPLEX PCR



The LabChip[®] GX Touch[™] nucleic acid analyzer:

- Microfluidic technology generates high-resolution data
- Optimal for DNA and RNA quantitation and sizing which can be done in seconds using automated capillary electrophoresis separation.

ABSL-2 HOUSING



Lab Product Individually Ventilated Rack



Biosafety Cabinet



Personal Protective Equipment (PPE)

	CRE (ng/µl)				Mouse Genomic (ng/μl)				
Samples	D10*	D14*	D21*	D28*	D10	D14	D21	D28	
Adeno-Cre Cage #1 Mouse Body Swab	-**	-	-	-	-	-	5.5	-	
Adeno-Cre Cage #2 Mouse Body Swab	-	-	-	-	2.9	-	-	-	The P(
Adeno-Cre Cage #3 Mouse Body Swab	-	-	-	-	-	-	5.6	-	
Adeno-Cre Cage #4 Mouse Body Swab	-	-	-	-	-	-	-	1.3	sensiti
Adeno-Cre Cage #5 Mouse Body Swab	-	-	-	-	-	6.7	-	-	minim
Adeno-Cre Cage #1 Cage Swab	-	-	-	-	-	-	-	-	conies
Adeno-Cre Cage #2 Cage Swab	-	-	-	-	-	-	-	-	copies
Adeno-Cre Cage #3 Cage Swab	-	-	-	-	1.3	-	-	0.8	gene.
Adeno-Cre Cage #4 Cage Swab	-	-	-	-	1.5	2	1.4	-	
Adeno-Cre Cage #5 Cage Swab	-	-	-	-	3.4	-	-	-	
Saline Cage #1 Mouse Body Swab	-	-	-	-	-	1.1	-	-	
Saline Cage #2 Mouse Body Swab	-	-	-	-	-	-	-	-	
Saline Cage #3 Mouse Body Swab	-	-	-	-	4.2	1.4	11.9	-	
Saline Cage #4 Mouse Body Swab	-	-	-	-	-	-	-	1.4	
Saline Cage #5 Mouse Body Swab	-	-	-	-	-	-	0.4	-	* Time
Saline Cage #1 Cage Swab	-	-	-	-	-	-	-	-	cro ino
Saline Cage #2 Cage Swab	-	-	-	-	-	-	-	1.4	cremo
Saline Cage #3 Cage Swab	-	-	-	-	-	-	3.9	-	skak NI
Saline Cage #4 Cage Swab	-	-	-	-	3.5	-	6.2	-	^^ NO a
Saline Cage #5 Cage Swab	-	-	-	-	2.5	-	2.1	-	observ
Biosafety Cabinet	-				-				
Animal Holding Room Floor	-				-				
Cre (+)	20.6			9.3				10.7	

The PCR assay sensitivity was minimum of 50 copies for the Cre gene.

* Time post Adenocre inoculation.

** No amplification observed.

SUMMARY OF FIRST EXPERIMENT

· Adenoviral DNA was not detectable on the animal body and in cage environment after 10 days of intratracheal Adeno-Cre viral inoculation in mice.

SECOND EXPERIMENT

 Intratracheal inoculation with 2.5 x

- 8–10-week-old female C57BL/6J
- 107 PFU Adeno-Cre Virus
- Intranasal inoculation with 2.5 x 107 PFU Adeno-Cre Virus
- Control No Inoculation

- Sample type: Wet Swab of the mouse body and mouse cage
- Sampling time points: 4 hours, 24 hours, 3 days, 7 days, 10 days and 14 days postinoculation.
- PCR detection of Cre gene (215 bp) which is part of the Adeno-Cre was utilized to assess the presence of Adeno-Cre virus
- PCR detection of mouse genomic DNA (IL2 exon3 – 300 bp) was used as the positive control.

Adeno-Cre: Replicative defective human adenovirus serotype 5 with Cre-recombinase

	CRE (ng/µl)							Mouse Genomic (ng/μl)					
Samples	4 hr*	24 hr	3 day	7 day	10 day	14 day	4 hr	24 hr	3 day	7 day	10 day	14 day	
Intratracheal mouse # 1 Body Swab	_**	-	-	-	-	-	2.9	-	-	1.8	6.9	6.4	
Intratracheal mouse # 2 Body Swab	-	-	-	-	-	-	1.2	-	-	-	6.3	7.2	
Intratracheal mouse # 3 Body Swab	-	-	-	-	-	-	3	-	-	14	-	1.9	
Intratracheal mouse # 4 Body Swab	-	-	-	-	-	-	-	0.6	-	31.3	3.3	3.1	
Intratracheal Cage Sample	-	-	-	-	-	-	-		-	3.4	3.3	4.3	
Intranasal mouse # 1 Body Swab	-	-	-	-	-	-	2.3	1.4	-	6.4	3.7	1.7	
Intranasal mouse # 2 Body Swab	9.1	-	-	-	-	-	2.2	2.7	-	8.5	6.3	4.4	
Intranasal mouse # 3 Body Swab	-	6.9	-	-	-	-	3.3	-	-	1.6	4.4	-	
Intranasal mouse # 4 Body Swab	-	-	-	-	-	-	-	0.8	3	12.8	3.2	20.9	
Intranasal Cage Sample	7.5	-	-	-	4.5	-	-	-	-	-	6.8	1.8	
Control mouse # 1 Body Swab	-	-	-	-	-	-	-	-	3.4	5.8	15.7	-	
Control mouse # 2 Body Swab	-	-	-	-	-	-	3.3	1.1	-	8.1	-	-	
Control mouse # 3 Body Swab	-	-	-	-	-	-	1.3	-	-	3.8	5.9	-	
Control mouse # 4 Body Swab	-	-	-	-	-	-	8.6	-	8.5	-	2.8	22.3	
Control Cage Sample	-	-	-	-	-	-	-	-	-	0.7	3.3	-	
Cre (+)	20.6					9.3						10.7	

The PCR assay sensitivity was minimum of 50 copies for the Cre gene.

* Time post adeno-cre inoculation

****** No amplification observed.

SUMMARY OF SECOND EXPERIMENT

- Adenoviral DNA was not detectable on the animal body and in cage environment:
 - After 4 hours of intratracheal Adeno-Cre viral inoculation in mice, even with the wet swab.
 - After 10 days of intranasal Adeno-Cre viral inoculation in mice.

CONCLUSIONS

- This data demonstrates that adenoviral DNA dissipates quickly after Adeno-Cre inoculation in mice, which helped institutional biosafety committee at NCI Frederick in determining the length of ABSL-2 housing of mice (biocontainment) post Adeno-Cre virus inoculation.
- Two weeks (14 days) of ABSL-2 housing provides adequate safety controls for studies involving the use of Adenoviral vectors in mice.

ACKNOWLEDGEMENTS

- Animal Diagnostic Laboratory (ADL)
 - Dr. Wang-Ting Hsieh
- · Center for Advanced Pre-Clinical Research (CAPR)
 - Dr. Zoe Weaver Ohler
 - Deborah Householder
- Institutional Biosafety Committee at NCI Frederick

